Global Expression Analysis of Well-Differentiated Pancreatic Endocrine Neoplasms Using Oligonucleotide Microarrays

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5988-5995

  Maitra, Anirban ^a,e   Hansel, Donna E ^a   Argani, Pedram ^a   Ashfaq, Raheela ^b   Rahman, Ayman ^a   Naji, Ali ^c   Deng, Shaoping ^c   Geradts, Joseph ^d   Hawthorne, Lesley Ann ^d   House, Michael G ^a   Yeo, Charles J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD99 ANTIGEN; PROTEIN; PROTEIN MIC2; PROTEIN P21; UNCLASSIFIED DRUG;

ADULT; AF10 GENE; ARTICLE; CD31 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FIBRONECTIN GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GROWTH FACTOR GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IGFBP3 GENE; IMMUNOHISTOCHEMISTRY; JUND GENE; MALE; MELCAM GENE; MLLT10 GENE; MUC18 GENE; ONCOGENE; PANCREAS ISLET CELL; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; RNA EXTRACTION; VALIDATION PROCESS;

ADULT; CELL DIFFERENTIATION; ENDOCRINE GLAND NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 0347364774     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Solcia, E., Rindi, G., Paolotti, D., La Rosa, S., Capella, C., and Fiocca, R. Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann. Oncol., 10 (Suppl. 2): S9-S15, 1999.
2. Solcia, E., Kloppel, G., and Sobin, L. H. Histological Typing of Endocrine Tumors. New York: Springer-Verlag, 2001.
3. Phan, G. Q., Yeo, C. J., Hruban, R. H., Lillemoe, K. D., Pitt, H. A., and Cameron, J. L. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J. Gastrointest. Surg., 2: 472-482, 1998.
4. Kloppel, G., Solcia, E., Capella, C., and Heitz, P. U. Classification of neuroendocrine tumours. Ital. J. Gastroenterol. Hepatol., 31 (Suppl. 2): S111-S116, 1999.
5. La Rosa, S., Sessa, F., Capella, C., Riva, C., Leone, B. E., Klersy, C., Rindi, G., and Solcia, E. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch., 429: 323-333, 1996.
6. Lee, C. S., Charlton, I. G., Williams, R. A., Dhillon, A. P., and Rode, J. Malignant potential of aneuploid pancreatic endocrine tumours. J. Pathol., 169: 451-456, 1993.
7. Rigaud, G., Missiaglia, E., Moore, P. S., Zamboni, G., Falconi, M., Talamini, G., Pesci, A., Baron, A., Lissandrini, D., Rindi, G., Grigolato, P., Pederzoli, P., and Scarpa, A. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res., 61:285-292, 2001.
8. Gumbs, A. A., Moore, P. S., Falconi, M., Bassi, C., Beghelli, S., Modlin, I., and Scarpa, A. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J. Surg. Oncol., 81: 45-53, discussion 54, 2002.
9. Iacobuzio-Donahue, C., Maitra, A., Olsen, M., Lowe, A., van Heek, N. T., Rosty, C., Walter, K., Sato, N., Parker, A., Ashfaq, R., Jaffee, E., Ryu, B., Jones, J., Eshelman, J., Yeo, C. J., Cameron, J. L., Kern, S. E., Hruban, R. H., Brown, P. O., and Goggins, M. Exploration of global expression patterns in pancreatic adenocarcinomas using cDNA microarrays. Am. J. Pathol., 162: 1151-1162, 2003.
10. Iacobuzio-Donahue, C. A., Maitra, A., Shen-Ong, G. L., van Heek, T., Ashfaq, R., Meyer, R., Walter, K., Berg, K., Hollingsworth, M. A., Cameron, J. L., Yeo, C. J., Kern, S. E., Goggins, M., and Hruban, R. H. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol., 160: 1239-1249, 2002.
11. Markmann, J. F., Deng, S., Huang, X., Velidedeoglu, E., Desai, N. M., Wolf, B., Matschinsky, F., Barker, F., and Naji, A. Successful human islet transplantation from single donors. Ann. Surg., in press, 2003.
12. Li, C., and Wong, W. H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA, 98: 31-36, 2001.
13. Luo, J., Zha, S., Gage, W. R., Dunn, T. A., Hicks, J. L., Bennett, C. J., Ewing, C. M., Platz, E. A., Ferdinandusse, S., Wanders, R. J., Trent, J. M., Isaacs, W. B., and De Marzo, A. M. α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res., 62: 2220-2226, 2002.
14. Argani, P., Rosty, C., Reiter, R. E., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Ryu, B., Skinner, H. G., Goggins, M., Jaffee, E. M., Yeo, C. J., Cameron, J. L., Kern, S. E., and Hruban, R. H. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res., 61: 4320-4324, 2001.
15. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E., Yeo, C. J., Cameron, J. L., Kern, S. E., and Hruban, R. H. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res., 7: 3862-3868, 2001.
16. Hansel, D. E., Rahman, A., Hidalgo, M., Thuluvath, P. J., Lillemoe, K. D., Shulick, R., Ku, J. L., Park, J. G., Miyazaki, K., Ashfaq, R., Wistuba, I. I., Varma, R., Hawthorne, L., Geradts, J., Argani, P., and Maitra, A. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am. J. Pathol., 163: 217-229, 2003.
17. Debernardi, S., Bassini, A., Jones, L. K., Chaplin, T., Linder, B., de Bruijn, D. R., Meese, E., and Young, B. D. The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex. Blood, 99: 275-281, 2002.
18. Chaplin, T., Ayton, P., Bernard, O. A., Saha, V., Della Valle, V., Hillion, J., Gregorini, A., Lillington, D., Berger, R., and Young, B. D. A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood, 85: 1435-1441, 1995.
19. Furstenberger, G., and Senn, H. J. Insulin-like growth factors and cancer. Lancet Oncol., 3: 298-302, 2002.
20. Vadgama, J. V., Wu, Y., Datta, G., Khan, H., and Chillar, R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology (Basel), 57: 330-340, 1999.
21. Danen, E. H., and Yamada, K. M. Fibronectin, integrins, and growth control. J. Cell. Physiol., 189: 1-13, 2001.
22. Ruoslahti, E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res., 76: 1-20, 1999.
23. Labat-Robert, J. Fibronectin in malignancy. Semin. Cancer Biol., 12: 187-195, 2002.
24. Shih, I. M. The role of CD146 (Mel-CAM) in biology and pathology, J. Pathol., 189: 4-11, 1999.
25. 1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
26. 2 arrest after DNA damage. Science (Wash. DC), 282: 1497-1501, 1998.
27. Gelin, C., Aubrit, F., Phalipon, A., Raynal, B., Cole, S., Kaczorek, M., and Bernard, A. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product, EMBO J., 8: 3253-3259, 1989.
28. Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., and Herman, J. G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 343: 1350-1354, 2000.
29. Tran, H., Brunet, A., Grenier, J. M., Datta, S. R., Fornace, A. J., Jr., DiStefano, P. S., Chiang, L. W., and Greenberg, M. E. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science (Wash. DC), 296: 530-534, 2002.
30. Venturelli, D., Martinez, R., Melotti, P., Casella, I., Peschle, C., Cucco, C., Spampinato, G., Darzynkiewicz, Z., and Calabretta, B. Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells. Proc. Natl. Acad. Sci. USA, 92: 7435-7439, 1995.
31. Weitzman, J. B., Fiette, L., Matsuo, K., and Yaniv, M. JunD protects cells from p53-dependent senescence and apoptosis. Mol. Cell, 6: 1109-1119, 2000.
32. Choi, Y. L., Oh, Y. L., Kim, S. H., Park, C. K., and Ahn, G. Comparative study of non-functional islet cell tumors and pancreatic solid and papillary neoplasms: biological behavior and immunohistochemistry. Pathol. Int., 52: 358-366, 2002.
33. Canavese, G., Azzoni, C., Pizzi, S., Corleto, V. D., Pasquali, C., Davoli, C., Crafa, P., Delle Fave, G., and Bordi, C. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum. Pathol., 32: 1094-1101, 2001.
34. Wu, G. J., Varma, V. A., Wu, M. W., Wang, S. W., Qu, P., Yang, H., Petros, J. A., Lim, S. D., and Amin, M. B. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate, 48: 305-315, 2001.
35. Johnson, J. P. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev., 18: 345-357, 1999.
36. Shih, I. M., Wang, T. L., and Westra, W. H. Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms. Clin. Cancer Res., 2: 569-575, 1996.
37. Sers, C., Riethmuller, G., and Johnson, J. P. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res., 54: 5689-5694, 1994.
38. Goodfellow, P. J., Darling, S. M., Thomas, N. S., and Goodfellow, P. N. A pseudoautosomal gene in man. Science (Wash. DC), 234: 740-743, 1986.
39. Ambros, I. M., Ambros, P. F., Strehl, S., Kovar, H., Gadner, H., and Salzer-Kuntschik, M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer (Phila.), 67: 1886-1893, 1991.
40. Movahedi-Lankarani, S., Hruban, R. H., Westra, W. H., and Klimstra, D. S. Primitive neuroectodermal tumors of the pancreas: a report of seven cases of a rare neoplasm. Am. J. Surg. Pathol., 26: 1040-1047, 2002.
41. Maitra, A., Weinberg, A. G., Schneider, N., and Patterson, K. Detection of t(11;22)(q24;q12) translocation and EWS-FLI-1 fusion transcript in a case of solid pseudopapillary tumor of the pancreas. Pediatr. Dev. Pathol., 3: 603-605, 2000.
42. Kim, S. H., Shin, Y. K., Lee, I. S., Bae, Y. M., Sohn, H. W., Suh, Y. H., Ree, H, J., Rowe, M., and Park, S. H. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood, 95: 294-300, 2000.
43. Lee, I., Kim, M. K., Choi, E. Y., Mehl, A., Jung, K. C., Gil, M. C., Rowe, M., and Park, S. H. CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB. Blood, 97: 3596-3604, 2001.
44. Shen, L., Dean, N. M., and Glazer, R. I. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Cα antisense oligonucleotide. Mol. Pharmacol., 55: 396-402, 1999.
45. Collard, T. J., Guy, M., Butt, A. J., Perks, C. M., Holly, J. M., Paraskeva, C., and Williams, A. C. Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis (Lond.), 24: 393-401, 2003.
46. Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M. E., Koo, J., Hartwick, W., Hoffma, B., and Hood, N. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res. Treat., 74: 65-76, 2002.
47. Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., and Sondak, V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond.), 406: 536-540, 2000.
48. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes R. O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature (Lond.), 406: 532-535, 2000.
49. Humphries, M. J., Olden, K., and Yamada, K. M. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science (Wash. DC), 233: 467-470, 1986.
50. Marty, C., Odermatt, B., Schott, H., Neri, D., Ballmer-Hofer, K., Klemenz, R., and Schwendener, R. A. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br. J. Cancer, 87: 106-112, 2002.